Related Experiment Videos
Clinical experience in coronary bypass surgery for abciximab-treated patients
1Legacy Good Samaritan Hospital, Northwest Surgical Associates, Portland, Oregon, USA. jlemmerjr@aol.com
Insights
Abciximab, an antiplatelet drug, raises bleeding concerns for patients needing coronary artery bypass graft (CABG) surgery. This review examines literature and emergency CABG cases to guide management.
Area of Science:
- Cardiology
- Vascular Surgery
- Pharmacology
Background:
- Abciximab is a potent platelet aggregation inhibitor.
- Patients on abciximab undergoing coronary artery bypass graft (CABG) surgery face increased bleeding risks.
- Effective management strategies are crucial for this patient population.
Purpose of the Study:
- To review existing literature on CABG in abciximab-treated patients.
- To present clinical outcomes of emergency CABG in 12 patients receiving abciximab.
- To offer management recommendations for abciximab-treated patients requiring urgent surgery.
Main Methods:
- Literature review of published studies on abciximab and CABG.
- Retrospective analysis of 12 emergency CABG cases in abciximab-treated patients.
- Synthesis of findings to develop clinical management suggestions.
Main Results:
- Bleeding complications are a significant concern in abciximab-treated patients undergoing CABG.
- Emergency CABG in this cohort presents specific challenges and outcomes.
- Management strategies can mitigate risks associated with abciximab and CABG.
Conclusions:
- Careful consideration of bleeding risks is essential for abciximab-treated patients requiring CABG.
- Specific protocols may be necessary for managing emergency CABG in patients on abciximab.
- Further research can refine perioperative management for improved patient outcomes.
Abstract:
Abciximab effectively inhibits platelet aggregation and, therefore, there is considerable concern regarding bleeding complications in patients who require coronary artery bypass graft (CABG) surgery while affected by the drug. This presentation reviews the available published literature regarding CABG in abciximab-treated patients, the clinical results of emergency CABG in 12 patients, and management suggestions for the abciximab-treated patient requiring emergency surgery.